logo
Singapore to be part of new NGO coalition to tackle drug trafficking, abuse: Shanmugam

Singapore to be part of new NGO coalition to tackle drug trafficking, abuse: Shanmugam

Singapore to be part of new NGO coalition to tackle drug trafficking, abuse: Shanmugam
Source: Straits Times
Article Date: 16 May 2025
Author: Andrew Wong
The group, called the Asia-Pacific Confederation against Drugs (APCD), will push for the creation of drug-free societies and stronger efforts to reduce the demand for drugs.
Singapore will be part of a new regional coalition of non-governmental organisations (NGOs) in the fight against drug trafficking and drug abuse.
The group, called the Asia-Pacific Confederation against Drugs (APCD), will push for the creation of drug-free societies and stronger efforts to reduce the demand for drugs.
The founding group will include members from Singapore, Malaysia, Indonesia, the Philippines and Hong Kong.
On May 15, Home Affairs Minister K. Shanmugam announced the formation of the coalition and said Singapore will be represented by the Singapore Anti-Narcotics Association.
Mr Shanmugam, who was accompanied by Minister of State for Home Affairs and National Development Muhammad Faishal Ibrahim, was speaking at the 2025 Asia-Pacific Forum Against Drugs held at Furama RiverFront Hotel in Havelock Road.
More than 300 coalition members, NGOs, partners, overseas correctional officers and local government officials are expected to attend the forum, which is taking place from May 15 to 17.
Mr Shanmugam, who is also Law Minister, said the APCD will strengthen regional cooperation through joint programmes and speak up against the rising tide of liberal policies and misinformation on drugs.
He announced this in the wake of the rising threat of potent synthetic drugs like fentanyl.
He said Malaysia had detected traces of the opioid in its sewage systems in March, suggesting that locals were abusing the drug there.
Said Mr Shanmugam: '(Fentanyl) is 50 times more potent than heroin, and its effects have been devastating.
'Between 2018 and 2022, or a five-year period, over 250,000 Americans died from fentanyl overdose. In 2022 alone, there were about 200 people dying in the US every single day.'
Mr Shanmugam added that deaths from fentanyl overdose in the US outnumbered the number who died in all of America's wars, including World War II and the wars in Korea, Vietnam and Afghanistan.
He said that unlike traditional plant-based drugs like cocaine or heroin, synthetic drugs such as methamphetamine, ketamine and fentanyl can be produced anywhere, even in the backyard of someone's house.
He noted that Myanmar is already one of the world's largest manufacturers of synthetic drugs and one of the biggest hosts of organised crime in the world.
'The situation in our region is also worrying... This is happening right at our doorstep. But given how interconnected the world is, what happens in Myanmar has deep implications all over the world,' Mr Shanmugam said.
He added that the rapid liberalisation of cannabis controls around the world has fuelled an increase in demand. A report by the United Nations estimated that there are 228 million cannabis users globally in 2022.
This is despite clear medical evidence that the use of cannabis can cause irreversible brain damage and serious psychiatric disorders, Mr Shanmugam said.
Statistics by the Central Narcotics Bureau show that in 2024, more than half of new cannabis abusers arrested in Singapore were below the age of 30, which suggested a growing permissiveness among young people towards the drug.
The report showed methamphetamine, heroin and cannabis were the most commonly abused drugs in Singapore that year.
Mr Shanmugam said a false narrative that cannabis is a 'soft drug' has been largely driven by commercial entities, similar to how tobacco corporations marketed smoking in the 1990s.
'(Tobacco corporations) ran advertisements of doctors saying smoking was good for health. They even introduced flavoured cigarettes to make them more appealing to the younger generation. Cannabis companies are likewise downplaying the risks, driven by profits.
'They are also trying to entice the young,' he said.
Mr Shanmugam said he had heard how cannabis lobby groups had argued for the drug's use as a medicinal tool when he attended international forums, including a United Nations forum.
He said he would support the use of cannabis for medical use only if a national medical association said it required the drug for treatment.
He added: 'But I won't support it if it is some company that is profiting from the use of cannabis that wants to legalise it without any controls, and is trying to do it in the form of candy to 10-year-olds.'
Mr Shanmugam stressed that Singapore will remain resolute in maintaining its tough stance against drugs, explaining that countries should be under no illusions about the difficulty in dealing with the global drug problem.
He said that the Republic's death penalty is most commonly used for drug traffickers and that these criminals are focused only on making money out of the death and misery of others.
He added: 'And so we make our laws very clear. We tell people, you traffic in drugs, you face the death penalty, and we impose it.'
Mr Shanmugam said the global drug trade is a multibillion-dollar industry with powerful, vested interests.
It exploits the vulnerable, corrupts state institutions, and undermines the will of governments to tackle this problem, undermining the fabric of societies, all for profit, he added.
He said: 'Challenging as it may be, we have to press on, because we have morality and right on our side, and it is the right thing to do.'
Source: The Straits Times © SPH Media Limited. Permission required for reproduction.
Print

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why this bread shop owner keeps on baking even with 'pain in every joint'
Why this bread shop owner keeps on baking even with 'pain in every joint'

CNA

time20 hours ago

  • CNA

Why this bread shop owner keeps on baking even with 'pain in every joint'

"It's okay if I lose mobility in two fingers, I can still use the other three," said 55-year-old baker Dennis Lim, who suffers from severe arthritis with visible deformities to both his hands. Despite the chronic pain, Mr Lim still pushes through 16-hour working days, kneading and shaping each loaf bread with dedication and perseverance. "A good loaf of bread is one that's made with heart," said Mr Lim, who has been baking for 27 years.

Kneading through the pain: Why this baker refuses to give up his craft despite severe arthritis
Kneading through the pain: Why this baker refuses to give up his craft despite severe arthritis

CNA

timea day ago

  • CNA

Kneading through the pain: Why this baker refuses to give up his craft despite severe arthritis

"It's okay if I lose mobility in two fingers, I can still use the other three," said 55-year-old baker Dennis Lim, who suffers from severe arthritis with visible deformities to both his hands. Despite the chronic pain, Mr Lim still pushes through 16-hour working days, kneading and shaping each loaf bread with dedication and perseverance. "A good loaf of bread is one that's made with heart," said Mr Lim, who has been baking for 27 years.

About 56% of affected Cordlife customers accept refund offer over mishandling of cord blood units
About 56% of affected Cordlife customers accept refund offer over mishandling of cord blood units

CNA

time2 days ago

  • CNA

About 56% of affected Cordlife customers accept refund offer over mishandling of cord blood units

SINGAPORE: About 56 per cent of affected Cordlife customers have accepted the refund offers made by the company after its mishandling of cord blood units. In a regulatory update on Friday (Jun 6), the private cord blood bank gave an update on the number of clients who have accepted its offers that were made in February and April 2024. The offers comprised a refund of the annual fees paid by affected clients from the onset of the "temperature excursion". For those affected, Cordlife had also offered to continue storing the cord blood units until their child reaches the age of 21 and to waive all future fees. When previously contacted by CNA in May last year, Cordlife declined to give the exact figure for the number of clients who had accepted the refunds. Its mishandling of cord blood units was first made public on Nov 30, 2023, when the Ministry of Health (MOH) revealed that investigations were ongoing. Seven tanks storing cord blood units were exposed to temperatures above acceptable limits. About 2,200 cord blood units were found damaged in one of the tanks, affecting at least 2,150 clients. In April last year, it was announced that another 5,300 cord blood units in a second tank and dry shipper were deemed "non-viable". Some customers are, however, continuing their legal action against the company. In a bourse update on the matter on Apr 1, the company said it had received on Mar 28 two letters of demand from lawyers acting for two groups of affected clients. One group is claiming for damages for breach of contract and negligence, while the other group is requesting for compensation for costs, among other warranties and undertakings from Cordlife. The company received its first letter of demand in May last year, while two other announcements were made in Aug 15, 2024 and Mar 1 on the same matter. In January, MOH renewed Cordlife's cord blood and human tissue banking service licences for a year, more than four months after it was allowed to resume its cord blood banking services in a limited manner. The company said on Friday it intends to host a series of townhall sessions - both in-person and online - to continue engaging customers to address their concerns. In a media invite last September, Cordlife talked up its new laboratory monitoring system to keep track of storage tank temperatures remotely and how it had hired more experienced laboratory staff and technicians to "elevate standards further". ACCREDITATION Cordlife added on Friday that it is also working closely with the Association for the Advancement of Blood & Biotherapies (AABB) and the Foundation for the Accreditation of Cellular Therapy (FACT) to restore both accreditations for its Singapore operations. In December 2023, it lost its cellular therapy accreditation with FACT. The suspension will last indefinitely, "at a minimum until FACT's investigations are completed and issues are resolved", Cordlife then said. AABB followed suit in August last year, with the international blood bank body withdrawing Cordlife's accreditation for the collection, processing, storage and distribution of cord blood. The company also provided an update on its Singapore operations, which were given the go-ahead by authorities to fully resume in January. "While collection rates remain below the company's pre-incident average, the full resumption of its Singapore operations represents an encouraging step forward in restoring client confidence and rebuilding operational momentum," it said. "The company has also strengthened and renewed its relationships with the medical community, particularly in Singapore. It has been proactively engaging hospitals, doctors, nurses and other stakeholders within the medical community to ensure they are fully informed on the company's rectification efforts and improved procedures," Cordlife added. Cordlife said it would continue to expand its outreach initiatives with the aim of returning to "pre-incident levels of performance" and would continue to update shareholders when there are material developments. For the financial year ending Dec 31, 2024, the group's revenue fell 50.4 per cent to S$27.6 million (US$21.4 million), with Cordlife primarily attributing the decline to the suspension of its Singapore operations. Its FY2024 revenue in Singapore was minus S$2 million, a steep reverse from S$24.7 million in 2023. NEW GROUP CEO In a separate bourse filing, Cordlife said it had appointed current group executive director Chen Xiaoling as its group CEO and Singapore CEO with effect from Thursday. The board said that it had considered Ms Chen's "proven track record" within the group as well as her qualifications, working experience, leadership capabilities and contributions. She will continue to serve as group executive director alongside her new roles, it added. Ms Chen was among nine people arrested earlier in connection with the mishandling of cord blood units. Non-independent non-executive directors, Mr Zhai Lingyun, Mr Yiu Ming Yiu and Mr Chow Wai Leong, Cordlife's chief financial officer Ms Thet Hnin Yi, the company's former Group CEO Tan Poh Lan, acting chairman Ho Choon Hou as well as independent directors Yeo Hwee Tiong and Titus Jim Cheong Tuck Yan were previously arrested and released on bail. In relation to a separate police report that was lodged by Cordlife's board of directors in April last year over "potential wrongdoings" of former employees amid an internal probe into why the cord blood units in one of the tanks were damaged, the company said it had not received any update regarding that case. "The company will continue to provide its full cooperation to the relevant authorities, as and when needed, for any subsequent investigations in connection with the police report," it said in a separate bourse filing on Friday.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store